Hu Xueqiang

[Expert Profile] Hu Xueqiang, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in neuroimmune diseases in China, working in the Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University. He has long focused on the clinical and basic research of multiple sclerosis, neuromyelitis optica, and central nervous system demyelinating diseases, and is one of the academic leaders in neuroimmunology in China.

[Education & Career] Professor Hu Xueqiang graduated from a renowned medical university, has been deeply involved in the field of neuroimmunology for decades, and further studied at famous international neuroimmunology research institutions. He has long served at The Third Affiliated Hospital of Sun Yat-sen University, holding academic positions such as leader of the Neuroimmunology Group of the Neurology Branch of the Chinese Medical Association and Chair of the Neurology Branch of the Guangdong Medical Association. He has presided over major research projects from the National Natural Science Foundation of China and the Ministry of Education, and is a representative scholar in neuroimmunology research in China.

[Areas of Expertise] Professor Hu specializes in the standardized diagnosis and treatment of central nervous system demyelinating diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). He has unique expertise in the differential diagnosis of central demyelinating diseases versus secondary demyelination caused by infection, tumor, and vascular disease. He is proficient in the individualized application of immunosuppressants, biologics, and novel targeted therapies, and is skilled in managing acute exacerbation phase treatment and long-term remission phase management, helping numerous patients control relapse, delay disability progression, and significantly improve the quality of life of neuroimmune disease patients.

[Academic Achievements & Industry Contributions] Professor Hu has led the establishment of a Chinese multiple sclerosis and neuromyelitis optica clinical cohort and biological sample repository, systematically studying the epidemiological characteristics, clinical phenotypes, and prognostic factors of neuroimmune diseases in China, with research findings published multiple times in authoritative domestic and international journals. He has led the development of Chinese guidelines and expert consensus statements for multiple sclerosis and neuromyelitis optica diagnosis and treatment, actively promoted the standardized clinical application of novel DMT (disease-modifying therapy) drugs in China, and led multi-center clinical trials to provide important evidence-based support for improving drug accessibility. He has trained a large number of neuroimmune specialists, promoting Chinese neuroimmunology from catching up to keeping pace internationally, with significantly improved overall standards.

[Clinical Practice & Outstanding Contributions] For decades on the clinical front lines, Professor Hu has treated tens of thousands of neuroimmune disease patients, including many difficult cases that went undiagnosed after traveling across multiple regions nationwide. Leading his team, he has established a neuroimmune specialist clinic and multidisciplinary collaboration model, providing patients with a full-chain service from diagnosis and treatment to rehabilitation and follow-up. He has been invited to deliver keynote speeches at national academic conferences on multiple occasions, and has conducted standardized neuroimmune diagnosis and treatment training at the grassroots level. He is the neuroimmune disease expert whom patients consider "most trustworthy."

[Honors & Reputation] Professor Hu Xueqiang serves as Chair of the Neuroimmunology Branch of the Chinese Immunological Society and a standing committee member of the Neurology Branch of the Chinese Medical Association, among other academic positions. He has presided over grants from the National Natural Science Foundation of China and major provincial and ministerial projects, and is one of the founders of neuroimmunology as a discipline in China. He has led large-scale clinical research on central nervous system demyelinating diseases including multiple sclerosis and neuromyelitis optica spectrum disorders, promoted the standardized application and improved accessibility of novel immunotherapies in China, participated in the development of Chinese neuroimmune disease diagnosis and treatment guidelines and expert consensus statements, and edited multiple neurology monographs. For decades on the clinical front lines, he has helped numerous demyelinating disease patients delay disability progression and return to normal life, trained a large number of neuroimmune professionals, and is deeply respected by patients and peers alike.